glp-1 obesity drug news oct 21 2025 Outlook for in 2025: more than a transition year GLP-1 Pipeline Update: August 2025
Description
Individuals with obesity are 35 % more likely to be deficient in vitamin D compared to those with a normal body weight [33], highlighting the importance of vitamin D supplementation with GLP-1RAs as many are likely starting at a deficient level
Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression
Novo Nordisk's incretin therapies Ozempic/Wegovy stand amongst the biggest breakthroughs in the history of the industry
With obesity linked to hypertension, dyslipidemia, sleep apnea, cardiovascular disease, fatty liver disease, and kidney complications, GLP-1 drugs have become platform therapies rather than single-indication products
The following charts are based on general guidelines and clinical trials
Based on the time effect and injection volume, GLP-1RAs can be categorized as either short-acting or long-acting
